Inclusion Criteria:

1. Patients with GI disorders who have failed standard therapy.

2. Age 16 or older

3. Symptoms or manifestations of: a) gastroparesis; b) refractory GERD including
persistent esophagitis, refractory heartburn, reflux-related laryngitis, and
respiratory symptoms; or c) severe dyspepsia.

4. Completion of a comprehensive evaluation, including clinical history and physical
examination, to eliminate other causes of their symptoms.

5. Patient has signed the informed consent document agreeing to the use of the study
drug, domperidone.

6. WBC with differential greater than 3,000/ml; alkaline phosphatase less than 1.5 x
upper limit of normal; ALT less than 2 x upper limit of normal; AST less than 2 x
upper limit of normal; bilirubin less than or equal to 2 x upper limit of normal; BUN
less than 2 x upper limit of normal; creatinine less than 1.5 x upper limit of
normal; stable hemoglobin greater than or equal to 8.0 g/dl; potassium between range
of 3.0 to 5.5.

Exclusion Criteria:

1. Patients with the following cardiac diagnoses: Ventricular tachycardia or
fibrillation; Torsade des Pointes; clinically significant bradycardia; sinus node
dysfunction; heart block; prolonged QTc interval (QTc > 450 milliseconds for males,
QTc > 470 milliseconds for females); valvular, ischemic, or pulmonary heart disease;
cardiomyopathy; history of heart failure

2. Patients who are receiving antiarrhythmic medications with action on repolarization
times (with prolongation of the QTc interval)

3. Patients who are receiving monoamine oxidase (MAO) inhibitors

4. Patients with a history of or active liver failure

5. Clinically significant electrolyte disorders including sodium < 130 or > 145 and/or
potassium < 3.0 or > 5.5

6. GI hemorrhage or obstruction experienced within the previous 6 weeks

7. Presence of a prolactinoma (prolactin-releasing pituitary tumor)

8. Pregnant or breast-feeding female (Women of childbearing potential [WOCBP], defined
as not post-menopausal for 12 months or without previous surgical sterilization, must
have a negative urine pregnancy test within 30 days of the first administration of
domperidone and must either commit to continued abstinence from heterosexual
intercourse or use an effective method of birth control during the course of the
study)

9. Known allergy to domperidone